Clinical Commander

Back to dossier
cardio.acute-hf.chemotherapy-induced.v1PRODUCTION
cardio.acute-hf.chemotherapy-induced.v1

Acute HF — Chemotherapy / cancer therapy-induced cardiomyopathy (CTRCD)

cardiologyacuteadult
Hard-required inputs
0 / 8
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

CTRCD = LVEF drop ≥10% to <50% OR GLS decline >15% from baseline during cancer therapy; 4 mechanisms (anthracycline cumulative; HER2 reversible; TKI HTN-mediated; ICI myocarditis fulminant); cancer prognosis informs intensity

Inputs
2
Actions
0
Advance rule
Set
Advance when

CTRCD subtype identified

Patient inputs (10)

Age >65 increases CTRCD risk; affects cancer-therapy continuation decision

Cancer prognosis informs HF treatment intensity + cardiac transplant candidacy

Anthracycline cumulative dose (mg/m²); HER2 inhibitor agent (trastuzumab Type II reversible; pertuzumab adds risk); TKI / ICI agent identity drives diagnostic + treatment pathway

Cardiorenal screen + dose adjustment for ACEi/ARB/SGLT2i

Baseline echo before cancer therapy + serial echos with strain (GLS) — GLS decline >15% predicts LVEF drop (Plana ASE/EACVI 2014 PMID 25172399)

Serial troponin during cancer therapy — early CTRCD biomarker; ICI myocarditis screening (any troponin elevation in ICI patient is concerning)

NT-proBNP elevation suggests cardiac strain; trend during therapy

TKI-related HTN common (sunitinib, sorafenib); SBP guides afterload reduction choice

Cardiac MRI with T1/T2 mapping + LGE for ICI myocarditis (subepicardial LGE pattern); also for anthracycline late-effect characterization

ICI myocarditis often co-occurs with myositis / myasthenia / hepatitis; concomitant irAE raises suspicion

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningici_myocarditis_fulminant
    ICI patient with new troponin elevation + LVEF drop OR new heart block OR ventricular arrhythmia OR cardiogenic shock — fulminant ICI myocarditis (~50% mortality)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereanthracycline_cumulative_dose_limit_with_active_decompensation
    Patient with cumulative doxorubicin ≥450 mg/m² (or equivalent) presenting with new HF symptoms — late-onset anthracycline CTRCD
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecancer_recurrence_risk_versus_continuing_therapy
    Active cancer with ongoing treatment response, but CTRCD with severely reduced LVEF — joint decision on cancer-therapy continuation vs holding
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatetrastuzumab_bb_up_titration_intolerance
    Patient on trastuzumab with LVEF drop, started on BB, but unable to up-titrate due to hypotension or bradycardia — trastuzumab Type II CTRCD usually reversible but BB intolerance complicates GDMT
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

CTRCD subtype-aware ADHF — GDMT 4-pillar (Cardinale 2015 PMID 25956652) + high-dose steroid for ICI myocarditis (Mahmood JACC 2018 PMID 29567210) + cancer-therapy continuation decision
axis: ctrcd_subtype_aware_phenotype
Selected axis "CTRCD subtype-aware ADHF — GDMT 4-pillar (Cardinale 2015 PMID 25956652) + high-dose steroid for ICI myocarditis (Mahmood JACC 2018 PMID 29567210) + cancer-therapy continuation decision" by default fallback (first axis)
  • furosemide
    first line
    loop_diuretic
    40-80 mg IV bolus then 5-10 mg/h infusion • IV • as scheduled
    triggers: ctrcd_with_pulmonary_edema
    DOSE PMID 21366472 high-dose IV bolus arm
    rxcui 4603
  • carvedilol
    first line
    beta_alpha_blocker
    3.125 mg PO BID titrate • PO • BID
    triggers: ctrcd_with_lvef_below_40_stable
    OVERCOME PMID 23083779 cardioprotection in cancer therapy; CAPRICORN PMID 11356436 + COPERNICUS PMID 11386262; ESC cardio-onc 2022 (PMID 36017575) Class I
    rxcui 20352
  • enalapril
    first line
    acei
    2.5 mg PO BID titrate • PO • BID
    triggers: ctrcd_with_lvef_below_40_stable_renal_function
    Cardinale 2015 PMID 25956652 — enalapril cardioprotection in anthracycline CMP; full LVEF recovery in 42% if started early; ESC cardio-onc 2022
    rxcui 203123
  • sacubitril-valsartan
    first line
    arni
    24/26 mg PO BID titrate • PO • BID
    triggers: ctrcd_with_lvef_below_40_acei_intolerant_or_de_novo_hf
    PIONEER-HF PMID 30403955; SCOT preliminary data supports ARNI in cancer therapy CMP; ESC cardio-onc 2022 Class IIa
    rxcui 1656328
  • spironolactone
    first line
    mra
    12.5-25 mg PO daily • PO • daily
    triggers: ctrcd_with_lvef_below_40_k_below_5_egfr_above_30
    RALES PMID 10471456; ESC cardio-onc 2022 Class I; PROACT trial (cardio-onc spironolactone) preliminary support
    rxcui 9997
  • empagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily • PO • daily
    triggers: ctrcd_with_lvef_below_40_egfr_above_20
    EMPULSE PMID 35347356; emerging evidence in CTRCD (ERASE-AF cardio-onc subgroups); ESC cardio-onc 2022 Class IIa
    rxcui 1545653
  • methylprednisolone
    first line
    systemic_corticosteroid
    1 g IV daily ×3-5 d then taper • IV • daily
    triggers: ici_myocarditis_grade_3_or_4
    Mahmood JACC 2018 PMID 29567210 — high-dose steroid is FIRST-LINE for ICI myocarditis; delay = death; treat empirically while workup proceeds
    rxcui 6902
  • IVIG (immunoglobulin G)
    second line
    immunomodulator_pooled_ig
    2 g/kg IV divided over 2-5 days • IV • as scheduled
    triggers: ici_myocarditis_refractory_to_steroid_at_24_to_72h
    ICI myocarditis steroid-refractory salvage; ESMO + NCCN guidelines support
    rxcui 5666
  • abatacept
    second line
    ctla4_ig_immunomodulator
    10 mg/kg IV q2 weeks • IV • q2 weeks
    triggers: ici_myocarditis_refractory_to_steroid_and_ivig
    Salem et al. case series — abatacept (CTLA-4 Ig) reverses ICI myocarditis by inhibiting T-cell activation; preferred over infliximab in HF (no TNF-α inhibition risk)
    rxcui 614391
  • infliximab
    rescue
    tnf_alpha_inhibitor
    5 mg/kg IV • IV • one dose then reassess
    triggers: ici_myocarditis_refractory_no_hf_otherwise
    TNF-α inhibitor for refractory ICI myocarditis; CAUTION: can worsen HF; AVOID if EF severely reduced; abatacept generally preferred
    rxcui 191831
  • dexrazoxane
    add on
    cardioprotectant_iron_chelator
    500 mg/m² IV 30 min before each anthracycline dose (10:1 dexrazoxane:doxorubicin ratio) • IV • with each anthracycline cycle
    triggers: high_risk_anthracycline_continuation_planned
    Cardioprotection in patients receiving cumulative anthracycline >300 mg/m²; reduces CTRCD incidence (Lipshultz NEJM 2010)
    rxcui 42736
  • normal saline 0.9%
    first line
    crystalloid
    500 mL IV bolus over 30 min if hypovolemic • IV • as needed
    triggers: ctrcd_with_hypovolemia_no_pulmonary_edema
    Many cancer patients are hypovolemic from poor PO intake / vomiting; cautious bolus before diuretic if uncertain volume status
    rxcui 9863

outpatient playbook — drug actions (2)

  1. 1. continue 4-pillar GDMT until LVEF normalized + stable ≥6-12 mo (avoid TRED-HF withdrawal harm)
    rxcui 1656328
    ARNI + BB + MRA + SGLT2i at max tolerated • PO • as scheduled
    trigger: Persistent HFrEF
    TRED-HF PMID 30429051; ESC cardio-onc 2022
  2. 2. cardioprotection with dexrazoxane if anthracycline continued
    rxcui 3639
    500 mg/m² IV pre-cycle • IV • with each cycle
    trigger: High-risk anthracycline continuation
    Lipshultz NEJM 2010

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Patient on active anthracycline / HER2 inhibitor / TKI / ICI therapy presenting with new dyspnea or LVEF drop; Surveillance echo: LVEF drop ≥10% to <50% OR GLS decline >15% from baseline during cancer therapy (CTRCD per ESC cardio-onc 2022); Serial troponin elevation during cancer therapy — early CTRCD biomarker; ICI myocarditis screening.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — Chemotherapy / cancer therapy-induced cardiomyopathy (CTRCD)** (cardio.acute-hf.chemotherapy-induced.v1).
Scope: CTRCD = LVEF drop ≥10% to <50% OR GLS decline >15% from baseline during cancer therapy; 4 mechanisms (anthracycline cumulative; HER2 reversible; TKI HTN-mediated; ICI myocarditis fulminant); cancer prognosis informs intensity

No severity triggers fired against current inputs.

Plan

Regimen axis: **CTRCD subtype-aware ADHF — GDMT 4-pillar (Cardinale 2015 PMID 25956652) + high-dose steroid for ICI myocarditis (Mahmood JACC 2018 PMID 29567210) + cancer-therapy continuation decision**.
1. furosemide 40-80 mg IV bolus then 5-10 mg/h infusion IV as scheduled (loop_diuretic, first line) — DOSE PMID 21366472 high-dose IV bolus arm
2. carvedilol 3.125 mg PO BID titrate PO BID (beta_alpha_blocker, first line) — OVERCOME PMID 23083779 cardioprotection in cancer therapy; CAPRICORN PMID 11356436 + COPERNICUS PMID 11386262; ESC cardio-onc 2022 (PMID 36017575) Class I
3. enalapril 2.5 mg PO BID titrate PO BID (acei, first line) — Cardinale 2015 PMID 25956652 — enalapril cardioprotection in anthracycline CMP; full LVEF recovery in 42% if started early; ESC cardio-onc 2022
4. sacubitril-valsartan 24/26 mg PO BID titrate PO BID (arni, first line) — PIONEER-HF PMID 30403955; SCOT preliminary data supports ARNI in cancer therapy CMP; ESC cardio-onc 2022 Class IIa
5. spironolactone 12.5-25 mg PO daily PO daily (mra, first line) — RALES PMID 10471456; ESC cardio-onc 2022 Class I; PROACT trial (cardio-onc spironolactone) preliminary support
6. empagliflozin 10 mg PO daily PO daily (sglt2_inhibitor, first line) — EMPULSE PMID 35347356; emerging evidence in CTRCD (ERASE-AF cardio-onc subgroups); ESC cardio-onc 2022 Class IIa
7. methylprednisolone 1 g IV daily ×3-5 d then taper IV daily (systemic_corticosteroid, first line) — Mahmood JACC 2018 PMID 29567210 — high-dose steroid is FIRST-LINE for ICI myocarditis; delay = death; treat empirically while workup proceeds
8. IVIG (immunoglobulin G) 2 g/kg IV divided over 2-5 days IV as scheduled (immunomodulator_pooled_ig, second line) — ICI myocarditis steroid-refractory salvage; ESMO + NCCN guidelines support
9. abatacept 10 mg/kg IV q2 weeks IV q2 weeks (ctla4_ig_immunomodulator, second line) — Salem et al. case series — abatacept (CTLA-4 Ig) reverses ICI myocarditis by inhibiting T-cell activation; preferred over infliximab in HF (no TNF-α inhibition risk)
10. infliximab 5 mg/kg IV IV one dose then reassess (tnf_alpha_inhibitor, rescue) — TNF-α inhibitor for refractory ICI myocarditis; CAUTION: can worsen HF; AVOID if EF severely reduced; abatacept generally preferred
11. dexrazoxane 500 mg/m² IV 30 min before each anthracycline dose (10:1 dexrazoxane:doxorubicin ratio) IV with each anthracycline cycle (cardioprotectant_iron_chelator, add on) — Cardioprotection in patients receiving cumulative anthracycline >300 mg/m²; reduces CTRCD incidence (Lipshultz NEJM 2010)
12. normal saline 0.9% 500 mL IV bolus over 30 min if hypovolemic IV as needed (crystalloid, first line) — Many cancer patients are hypovolemic from poor PO intake / vomiting; cautious bolus before diuretic if uncertain volume status

Setting playbook (outpatient) — Long-term cardio-oncology surveillance: serial echo with GLS at 3 mo, 6 mo, 12 mo; ICD evaluation if LVEF persistently <35% on full GDMT; survivorship clinic for anthracycline (lifelong); cancer-therapy continuation re-evaluation each cycle
13. continue 4-pillar GDMT until LVEF normalized + stable ≥6-12 mo (avoid TRED-HF withdrawal harm) ARNI + BB + MRA + SGLT2i at max tolerated PO as scheduled — Persistent HFrEF (TRED-HF PMID 30429051; ESC cardio-onc 2022)
14. cardioprotection with dexrazoxane if anthracycline continued 500 mg/m² IV pre-cycle IV with each cycle — High-risk anthracycline continuation (Lipshultz NEJM 2010)

Non-pharmacologic actions:
- Cardio-oncology clinic q3-6 mo
- Survivorship clinic annual lifelong if anthracycline (late-onset CTRCD can occur years after therapy)
- Cardiac rehab maintenance
- ICD evaluation if LVEF <35% at 3-6 mo on full GDMT
- Counsel re: pregnancy if patient of childbearing age (anthracycline residual cardiotoxicity in pregnancy)

AVOID / contraindication checks:
- Hold_anthracycline_if_lvef_drop_above_10_to_below_50 (ESC cardio onc 2022)
- Hold_trastuzumab_if_lvef_drop_to_below_50_or_above_10_drop_with_symptoms (FDA labeling); usually reversible with 6 8 wk pause + GDMT
- Hold_ici_permanently_for_grade_3_or_4_myocarditis (CTCAE; ESMO + NCCN)
- Start_methylprednisolone_empirically_for_suspected_ici_myocarditis_within_24h (delay = death; Mahmood PMID 29567210)
- Avoid_infliximab_in_severe_hf (TNF α inhibitor HF risk; abatacept preferred for ICI myocarditis with HF)
- Taper_steroid_slowly_over_4_to_6_weeks_after_ici_myocarditis (rebound risk if rapid taper)
- Dexrazoxane_only_for_high_cumulative_anthracycline_above_300_mg_m2 (concern about reducing antitumor efficacy in low risk patients)
- Joint_cardio_onc_decision_for_cancer_therapy_continuation (weigh tumor response vs HF severity)
- Beta_blocker_ace_inhibitor_in_all_ctrcd_with_lvef_below_40 (ESC cardio onc 2022 Class I)
- Check_for_concomitant_irae_in_ici_myocarditis (myositis CK, hepatitis AST/ALT, myasthenia ACh Ab) — combined irAE worse prognosis

Monitoring

Regimen monitoring:
- continuous telemetry for arrhythmia and block (ICI myocarditis high arrhythmia + heart block risk)
- serial troponin q6 to 8h until trending down (ICI myocarditis activity marker)
- serial echo with strain gls at baseline then per cycle then 3 to 6 mo post therapy (ESC cardio-onc 2022 surveillance schedule)
- cardiac mri at 3 to 6 mo for late effect characterization (anthracycline LGE pattern)
- daily weight strict io during acute phase
- q6 to 12h bmp during diuresis and steroid (hyperglycemia risk)
- concomitant irae screening for ici patients (CK, AST/ALT, glucose, TSH)

Setting (outpatient) monitoring:
- Quarterly clinic visits + echo
- Annual BNP/NT-proBNP
- Cancer surveillance per oncology

Follow-up plan: Cardio-oncology clinic at 2 weeks, 6 weeks, 3 months, 6 months; serial echo with GLS for LVEF recovery; cancer-therapy continuation decision re-evaluated each visit; survivorship clinic for late-effect screening if anthracycline (lifelong); ICD evaluation if LVEF persistently <35% on full GDMT
- Close-out criterion: cardio-oncology clinic + cancer-therapy plan + survivorship pathway documented

Monitoring phase: Continuous telemetry (block + VT/VF in ICI myocarditis), daily weight, hourly UOP, serial troponin q6-8h until trending down, daily BMP, daily echo until stable, repeat echo at 1-2 weeks for LVEF response

Disposition

Current setting: outpatient — Long-term cardio-oncology surveillance: serial echo with GLS at 3 mo, 6 mo, 12 mo; ICD evaluation if LVEF persistently <35% on full GDMT; survivorship clinic for anthracycline (lifelong); cancer-therapy continuation re-evaluation each cycle

Disposition criteria:
- Long-term continuation; cross-link to cardio.hfref.core.v1 if HFrEF persists past 12 mo; survivorship lifelong

Escalation triggers (move to higher acuity):
- Worsening LVEF despite GDMT → advanced HF + transplant evaluation (cancer-therapy disease-free interval matters)
- ICD therapy delivered → urgent EP
- Cancer recurrence requiring restart of cardiotoxic agent → joint cardio + onc decision

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] ICI patient with new troponin elevation + LVEF drop OR new heart block OR ventricular arrhythmia OR cardiogenic shock — fulminant ICI myocarditis (~50% mortality)
- [SEVERE] Patient with cumulative doxorubicin ≥450 mg/m² (or equivalent) presenting with new HF symptoms — late-onset anthracycline CTRCD
- [SEVERE] Active cancer with ongoing treatment response, but CTRCD with severely reduced LVEF — joint decision on cancer-therapy continuation vs holding

Citations

- ESC cardio-oncology 2022 + 2022 ACC/AHA HF + Cardinale 2015 enalapril cardioprotection + Mahmood ICI myocarditis JACC 2018 [PMID:36017575](https://pubmed.ncbi.nlm.nih.gov/36017575/)
- Cited evidence (PMID 35363499) [PMID:35363499](https://pubmed.ncbi.nlm.nih.gov/35363499/)
- Cited evidence (PMID 34447992) [PMID:34447992](https://pubmed.ncbi.nlm.nih.gov/34447992/)
- Cited evidence (PMID 38264914) [PMID:38264914](https://pubmed.ncbi.nlm.nih.gov/38264914/)
- Cited evidence (PMID 25956652) [PMID:25956652](https://pubmed.ncbi.nlm.nih.gov/25956652/)

Last reconciled with current guidelines: 2026-05-15.
References
  • ESC cardio-oncology 2022 + 2022 ACC/AHA HF + Cardinale 2015 enalapril cardioprotection + Mahmood ICI myocarditis JACC 2018 — PMID:36017575
  • Cited evidence (PMID 35363499) — PMID:35363499
  • Cited evidence (PMID 34447992) — PMID:34447992
  • Cited evidence (PMID 38264914) — PMID:38264914
  • Cited evidence (PMID 25956652) — PMID:25956652